ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Abbott Licenses Kidney Disease Drug

by Lisa M. Jarvis
October 4, 2010 | APPEARED IN VOLUME 88, ISSUE 40

Abbott Laboratories has agreed to pay $450 million for the right to sell Reata Pharmaceuticals’ bardoxolone outside the U.S. Bardoxolone is an oral antioxidant inflammatory modulator that turns on Nrf2, a protein that dictates the production of antioxidant and detoxification enzymes. The drug candidate has shown promise in two Phase II trials for chronic kidney disease, a condition affecting 30–40% of people with type 2 diabetes. The Abbott deal excludes some Asian markets, for which Kyowa Hakko Kirin has already licensed the drug.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment